{'fraction_non_alphanumeric': 0.030223390275952694, 'fraction_numerical': 0.00788436268068331, 'mean_word_length': 5.195121951219512, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Neutralizing humoral immunity has been the subject of intense investigation since early in HIV research. While virtually all HIV-positive patients have antibodies capable of binding to HIV Env protein, only a subset of these antibodies, termed neutralizing antibodies (NAb), are able to block viral entry into target cells. NAbs develop later than other immune responses – at least 12 weeks after infection [1, 2] – and initially target only the infecting strain. Over time, in many patients this response broadens to allow recognition of heterologous strains [3, 4]. It is generally thought that NAbs will be a critical component of a successful vaccine-elicited immune response.